Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells
A substantial number of Phase I and Phase II clinical trials of interleukin-2 (IL-2) alone or combined with adoptive transfer of lymphokine-activated killer (LAK) cells in the treatment of cancer patients had defined IL-2 pharmacokinetics in humans, some immunodulatory effects, toxicity and maximum tolerated doses, and a preliminary evaluation of antitumor activity of this novel approach to therapy [2, 3].
KeywordsToxicity Chromium Lymphoma Leukemia Oncol
Unable to display preview. Download preview PDF.
- 1.Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sodel PM (1988) In vivo induction of the lymphokine-activated killer phenomenon:interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res 48:1965–1971PubMedGoogle Scholar
- 2.Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SD, Seipp CAY, Custer MC, Rosenberg SA (1985) In vivo administration of purified human interleukin 2, II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2, J Immunol 135:2865–2875PubMedGoogle Scholar